Floatz logo

Rybelsus

Diabetes Mellitus, Type 2

Novo Nordisk A/SDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

142 Active assets in the Diabetes Mellitus, Type 2 cohort.

Asset / SponsorPhaseRating
Liraglutide
RenJi Hospital
Phase 4BBB
Semaglutide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Exenatide
Vivani Medical, Inc
Phase 4BBB
Cotadutide
AstraZeneca
Phase 2BBB
Dapagliflozin
Bhavya Bhavya, MD
Phase 4BBB

View all 50 →

Same molecule, other indications

Rybelsus is also rated in:

metabolic dysfunction-associated steatotic liver diseaseDormant
BB
Indicative ·
68 / 100
View asset →
obesity disorderDormant
BB
Indicative ·
67 / 100
View asset →
polycystic ovary syndromeDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →